columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
myfenax
teva b.v. - mycophenolatmofetil - graft afvisning - immunosuppressiva - myfenax er indiceret i kombination med ciclosporin og kortikosteroider til profylakse af akut transplantafstødning hos patienter, der modtager allogene nyre-, hjerte- eller levertransplantater.
enjaymo
sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - immunosuppressiva - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).
cellcept
roche registration gmbh - mycophenolatmofetil - graft afvisning - immunosuppressiva - cellcept er indiceret i kombination med ciclosporin og kortikosteroider til profylakse af akut transplantafstødning hos patienter, som modtager allogene nyre-, hjerte- eller levertransplantater.
darzalex
janssen-cilag international n.v. - daratumumab - multipelt myelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. i kombination med bortezomib, thalidomid og dexamethason til behandling af voksne patienter med nyligt diagnosticeret med myelomatose, der er berettiget til autolog stamcelletransplantation. i kombination med lenalidomid og dexamethason, eller bortezomib og dexamethason til behandling af voksne patienter med myelomatose, som har modtaget mindst én tidligere behandling. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. som monoterapi til behandling af voksne patienter med recidiverende og refraktær myelomatose, hvis tidligere behandling indgår en proteasome-hæmmer og et immunmodulerende agent, og som har vist, sygdommens progression på den sidste terapi. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
ecomectin vet. 10 mg/ml injektionsvæske, opløsning
eco animal health europe ltd. - ivermectin - injektionsvæske, opløsning - 10 mg/ml - får, kvæg, svin
ecomectin pour-on vet. 5 mg/ml pour-on, opløsning
eco animal health europe ltd. - ivermectin - pour-on, opløsning - 5 mg/ml - kvæg
cydectin pour-on vet. 0,5% pour-on, opløsning
orion pharma animal health a/s - moxidectin - pour-on, opløsning - 0,5% - kvæg
zepromec 5 mg/ml pour-on, opløsning
chanelle pharmaceuticals manufacturing limited - eprinomectin - pour-on, opløsning - 5 mg/ml - kvæg
recarbrio
merck sharp & dohme b.v. - imipenem, monohydrat, cilastatin natrium, relebactam monohydrat - gram-negative bakterie-infektioner - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 og 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..